Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
== Further reading == "Clean Water Act Analytical Methods". EPA. 2022-07-27. "Hazardous Waste Test Methods / SW-846". EPA. 2022-06-15. Eaton, Andrew D.; Greenberg, Arnold E.; Rice, Eugene W.; Clesceri, Lenore S.; Franson, Mary Ann H., eds. (2005). Standard Methods For the Examination of Water and Wastewater (21 ed.). American Public Health Association. ISBN 978-0-87553-047-5. Also available on CD-ROM and online by subscription.
== External links == "Food Packaging -- Roles, Materials, and Environmental Issues - IFT.org". www.ift.org. Retrieved 3 December 2018. Poly(hydroxyalkanoates) for Food Packaging: Application and Attempts towards Implementation
The Constitution of India was drafted by the Constituent Assembly of India between 1946 and 1949, despite the political disruptions of the Partition. The Government of India Act 1935 was used as a model and framework. Long passages from the Act were included. The constitution describes a federal state with a parliamentary system of democracy. The federal structure was notable for the strength of the central government, which exclusively controlled defence, foreign affairs, railways, ports, and currency. The President, the constitutional head of state, has reserve powers for taking over the administration of a state. The central legislature has two houses: the Lok Sabha, whose delegates are directly elected by the people in general elections every five years, and the Rajya Sabha, whose members are nominated by the elected representatives in the states. The Constitution also includes features not found in the 1935 Act. The definition of fundamental rights is based on the Constitution of the United States, and the constitutional directives, or goals of endeavour, are based on the Constitution of Ireland. An Indian institution recommended by the constitution is the panchayat or village committees. Untouchability is illegal (Article 17) and caste distinctions are derecognised (Articles 15(2) and 16(2)). The promulgation of the Indian Constitution transformed India into a republic within the Commonwealth. The prime minister of India is the head of government and exercises most executive power.
== Business and finance == CLS Group, a global financial market utility Celestica, New York Stock Exchange symbol CLS Communication, translation services CLS Holdings, UK investment company Core Labor Standards, ILO Crown Liquor Saloon, ornate bar in Belfast, Northern Ireland
In the synthesis of DNA templated combinatorial libraries, the ability of the DNA double helix to direct region-specific chemical reactions is harnessed by Gartner et al. The DNA- linked reagents are kept in close proximity. This is equivalent to the virtual increase of local concentration that is nearly constant within a distance of 30 nucleotides. The proximity effect helps reactions to proceed. Two libraries are synthesized. A template library containing at one end one of the BBs and its code followed by two annealing regions for the codes of the BBs of the two reagent libraries. Each of the two reagent libraries contains a coding oligonucleotide linked with cleavable bonds to the reagent (BB) capable of forming a bond with the already linked BB taking advantage of the proximity effect. The synthesis is realized in two steps as shown in the figure. Each step has three operations: mixing, annealing, coupling-cleaving.
Sources: en.wikipedia.org
Periungual angiofibromas are also termed Koenen's tumors, periungual fibromas, and subungual fibromas. In addition, these tumors were formerly regarded as a type of acral angiofibroma (see below description). These lesions present as multiple nodules or tumors under multiple finger and/or toe nails of individuals with tuberous sclerosis or in one case the Birt-Hogg-Dube syndrome. Periungual angiofibromas have also been reported to occur in individuals that do not have these genetic diseases. Periungual angiofibromas tumors can be highly mutilating finger/toe-nail lesions.
Pivampicillin (pivaloyloxymethyl ester of ampicillin) Bacampicillin Metampicillin (formaldehyde ester of ampicillin) Talampicillin Hetacillin (ampicillin conjugated to acetone) Epicillin is an aminopenicillin that has never seen widespread clinical use.
Dekaranger, Ban acquires a variant of the SP License called the Fire Squad License (ファイヤースクワッドライセンス, Faiyā Sukuwaddo Raisensu), which allows him to transform Murphy K-9 into his armor to assume Battlizer Mode (バトライザーモード, Batoriza Mōdo) where he gains a rocket booster pack and a pair of siren lasers. In this form, he wields a sword/rifle hybrid, which allows him to perform the Battlize Fire Drive (バトライズファイヤードライブ, Batoraizu Faiyā Doraibu) finisher. As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Ban has acquired a red-colored S.W.A.T. Mode vest to signify his membership in the Fire Squad. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, he acquires a variant of the SP License called the SP1 License (SP1ライセンス, Esu Pī Wan Raisensu), which allows him to transform into the armored Premiere Deka Red (プレミアデカレッド, Puremia Deka Reddo). While transformed, he wields the D-Sword Vega, which allows him to perform the Boost Slash (ブーストスラッシュ, Būsuto Surasshu) finisher. Ban is portrayed by Ryuji Sainei (載寧 龍二, Sainei Ryūji).
== Corporate structure == TikTok Ltd was incorporated in the Cayman Islands in the Caribbean and is based in both Singapore and Los Angeles. It owns entities which are based respectively in Australia (which also runs the New Zealand business), United Kingdom (also owns subsidiaries in the European Union), and Singapore (owns operations in Southeast Asia and India). A spin-off company, TikTok USDS Joint Venture LLC was formed on 22 January 2026 to handle TikTok and other ByteDance properties in the United States. Oracle Corporation, MGX Fund Management Limited, Silver Lake each hold a 15% stake, ByteDance holds a 19.9% stake, and the remaining 35.1% is shared between Dell Technologies founder Michael Dell and Vastmere Strategic Investments. Its parent company, Beijing-based ByteDance, is owned by founders and Chinese investors, other global investors, and employees. One of ByteDance's main domestic subsidiaries is owned by Chinese state funds and entities through a 1% golden share. Employees have reported that multiple overlaps exist between TikTok and ByteDance in terms of personnel management and product development. TikTok says that since 2020, its US-based CEO is responsible for making important decisions, and has downplayed its China connection.
Sources: en.wikipedia.org
== External links == Description of the TGF beta producing genes at ncbi.nlm.nih.gov Diagram of the TGF beta signaling pathway at genome.ad.jp The TGF-beta system—Nature Reviews Molecular Cell Biology SMART:TGFB domain annotation—European Molecular Biology Laboratory Heidelberg TGF-beta at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Biochemists Solve Structure Of TGF-Beta And Its Receptor. 2008 – shows TGF-β3 dimer in TGFB-receptor Measurement of Human Latent TGF-β1[link removed] TGF beta pathway diagram IntroPro Entry - IPR016319
=== Pitfalls === Notably, attempts to surgically remove bone in a FOP patient may result in explosive growth of new bone. While undergoing anesthesia, people with FOP may encounter difficulties with intubation, restrictive pulmonary disease, and changes in the electrical conduction system of the heart. Activities that increase the risk of falling or soft tissue injury should be avoided, as even minor trauma may provoke heterotopic ossification. Intramuscular injections, including immunizations, should likewise be avoided in individuals with FOP, as these can also trigger ossification. Currently, surgery is not usually recommended for people with FOP as it can incite rapid bone formation at incision sites or where sutures have been applied to muscle or connective tissue. Life-saving surgery may be considered; however, developing a surgical plan with input from a FOP specialist may be considered best practice. Surgical release of joint contractures is generally unsuccessful and risks new, trauma-induced heterotopic ossification.
According to a January 27, 2022 Alberta Health Services news release, as of July 1, the private company, DynaLIFE Medical Labs, would expand their community laboratory services across the province, while in-hopital laboratory testing would remain with Alberta Precision Laboratories. By June 29, 2020, when Alberta Health Services announced their intentions to privatize community lab services, many of these labs were run by a wholly owned AHS public subsidiary, Alberta Precision Laboratories (APL). The president of the Health Sciences Association of Alberta (HSAA)—representing 6,000 laboratory technicians across Alberta—raised concerns about job loss. According to the December 31, 2019 Ernst & Young commissioned report—"Alberta Health Services Performance Review", there were 210 sites across Alberta conducting 81 million tests, and employing 3,819 full-time workers with an annual operating budget of $800 million. Of these sites, 174 were run by the APL, and 36 were operated by the private provider, DynaLIFE. Friends of Medicare expressed concern about the AHS contract with the private, for-profit DynaLIFE, replacing the public community medical laboratory services. The organization is concerned about the UCP government's privatization of the public health care system; with this most recent change expanding on similar privatization in "laundry services, surgical services, our continuing care system, EMS services, and others". DynaLIFE's 5-year contract with AHS was to end in March 2022.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.